Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-10-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating
patients with acute myeloid leukemia that has come back (relapsed) or does not respond to
treatment (refractory), or elderly patients with newly diagnosed acute myeloid leukemia who
are not candidates for intensive chemotherapy. Venetoclax may help block the formation of
growths that may become cancer. ASTX727 is the combination of a fixed dose of 2 drugs,
cedazuridine and decitabine. Cedazuridine may slow down how fast decitabine is broken down by
the body, and decitabine may block abnormal cells or cancer cells from growing. Giving
venetoclax and ASTX727 may help to control the disease.